- $309.15m
- $158.06m
- 39
- 21
- 50
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.03 | ||
| Price to Tang. Book | 2.03 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -57.35% | ||
| Return on Equity | -46.01% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and activation of a secondary immune mediated response. Its lead candidate, bel-sar, is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. Bel-sar consists of a human papillomavirus (HPV)-derived virus-like particle (VLP), conjugated to hundreds of infrared laser-activated molecules. It is evaluating the bel-sar in a Phase III CoMpass trial for the first line treatment of early-stage choroidal melanoma.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 13th, 2009
- Public Since
- October 29th, 2021
- No. of Shareholders
- 53
- No. of Employees
- 106
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 50,268,758
- Address
- 80 Guest Street, BOSTON, 01235
- Web
- https://aurabiosciences.com/
- Phone
- +1 6175008864
- Auditors
- Ernst & Young LLP
Upcoming Events for AURA
Aura Biosciences Inc at HC Wainwright BioConnect Investor Conference
Q1 2025 Aura Biosciences Inc Earnings Release
Aura Biosciences Inc at TD Cowen Technology, Media & Telecom Conference
Aura Biosciences Inc Annual Shareholders Meeting
Q2 2025 Aura Biosciences Inc Earnings Release
Similar to AURA
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the AURA BIOSCIENCES share price?
As of Today at 19:25 UTC, shares in AURA BIOSCIENCES are trading at $6.15. This share price information is delayed by 15 minutes.
How has the AURA BIOSCIENCES share price performed this year?
Shares in AURA BIOSCIENCES last closed at $6.15 and the price had moved by -20.85% over the past 365 days. In terms of relative price strength the AURA BIOSCIENCES share price has underperformed the S&P500 Index by -28.63% over the past year.
What are the analyst and broker recommendations for AURA BIOSCIENCES?
The overall consensus recommendation for AURA BIOSCIENCES is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the AURA BIOSCIENCES dividend yield?
AURA BIOSCIENCES does not currently pay a dividend.
Does AURA BIOSCIENCES pay a dividend?
AURA BIOSCIENCES does not currently pay a dividend.
When does AURA BIOSCIENCES next pay dividends?
AURA BIOSCIENCES does not currently pay a dividend.
How do I buy AURA BIOSCIENCES shares?
To buy shares in AURA BIOSCIENCES you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of AURA BIOSCIENCES?
As of the previous close price of $6.15, shares in AURA BIOSCIENCES had a market capitalisation of $309.15m.
Where are AURA BIOSCIENCES shares listed?
Here are the trading details for AURA BIOSCIENCES:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: AURA
What kind of share is AURA BIOSCIENCES?
Based on an overall assessment of its quality, value and momentum AURA BIOSCIENCES is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a AURA BIOSCIENCES share price forecast for 2025?
The analyst consensus target price for shares in AURA BIOSCIENCES is $22.00. That is 257.72% above the last closing price of $6.15.
Analysts covering AURA BIOSCIENCES currently have a consensus Earnings Per Share (EPS) forecast of -$2.16 for the next financial year.
Find out moreWhat is the trend in the AURA BIOSCIENCES share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AURA BIOSCIENCES. Over the past six months, its share price has underperformed the S&P500 Index by -39.13%.
As of the last closing price of $6.15, shares in AURA BIOSCIENCES were trading -25.33% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the AURA BIOSCIENCES PE Ratio?
The AURA BIOSCIENCES PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of AURA BIOSCIENCES?
AURA BIOSCIENCES' management team is headed by:
- David Johnson - CHM
- Elisabet de los Pinos - CEO
- Julie Feder - CFO
- Mark De Rosch - COO
- Cadmus Rich - OTH